SCHEMBL2367080

SCHEMBL2367080

COc1ccc(Nc2nc(C(N)=O)c(NC(=O)c3ccc(F)cc3)s2)cc1

nearest known ligand 0.70

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
TNIK Q9UKE5 17/20 0.70
MEN1 O00255 1/20 0.61
NPC1 O15118 1/20 0.61
KMT2A Q03164 1/20 0.61
TP53 P04637 2/20 0.59
MAPT P10636 2/20 0.59
LMNA P02545 1/20 0.59
POLB P06746 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3393549 1.00 TNIK (0.70) TNIKMEN1NPC1KMT2ATP53
SCHEMBL3398128 0.94 TNIK (0.77) TNIKMEN1NPC1KMT2ATP53
SCHEMBL2366979 0.90 TNIK (0.85) TNIKMEN1NPC1KMT2ATP53
SCHEMBL2367144 0.90 TNIK (0.71) TNIKTP53MAPTLMNAPOLB
SCHEMBL3393556 0.90 TNIK (0.66) TNIKTP53MAPTLMNAPOLB
SCHEMBL2367157 0.89 TNIK (0.73) TNIKTP53MAPTLMNAPOLB
SCHEMBL2367192 0.89 TNIK (0.78) TNIKMEN1KMT2ATP53MAPT
SCHEMBL2367385 0.88 TNIK (0.69) TNIKMEN1NPC1KMT2ATP53
SCHEMBL2367268 0.88 TNIK (0.68) TNIKTP53MAPTLMNAPOLB
SCHEMBL3396333 0.88 TNIK (0.86) TNIKTP53MAPTLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364149-B1 TNIK INHIBITOR AND THE USE NAT CANCER CT (JP) 2014-05-07 EP disclosed
EP-2364149-B1 TNIK INHIBITOR AND THE USE NAT CANCER CT (JP) 2014-05-07 EP disclosed
CN-102227218-A Tnik inhibitor and use thereof TESSHI YAMADA 2011-10-26 CN disclosed
EP-2364149-A1 TNIK INHIBITOR AND THE USE National Cancer Center (JP) 2011-09-14 EP disclosed
US-20100216795-A1 TNIK INHIBITOR AND THE USE YAMADA TESSHI 2010-08-26 US disclosed
US-20100216795-A1 TNIK INHIBITOR AND THE USE YAMADA TESSHI 2010-08-26 US disclosed
US-20100216795-A1 TNIK INHIBITOR AND THE USE YAMADA TESSHI 2010-08-26 US disclosed
WO-2010064111-A1 TNIK INHIBITOR AND THE USE YAMADA TESSHI (JP) 2010-06-10 WO disclosed
WO-2010064111-A1 TNIK INHIBITOR AND THE USE YAMADA TESSHI (JP) 2010-06-10 WO disclosed
US-20100137386-A1 TNIK INHIBITOR AND THE USE YAMADA TESSHI 2010-06-03 US disclosed
US-20100137386-A1 TNIK INHIBITOR AND THE USE YAMADA TESSHI 2010-06-03 US disclosed
US-20100137386-A1 TNIK INHIBITOR AND THE USE YAMADA TESSHI 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216795-A1 TNIK INHIBITOR AND THE USE TNIK, TNNI3K, TNK1 TNIK 1/4885MEN1 3798/4885NPC1 2281/4885
US-20100137386-A1 TNIK INHIBITOR AND THE USE TNIK, TNNI3K, TNK1 TNIK 1/4885MEN1 3959/4885NPC1 1709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.